Cartwright W S
National Institute on Drug Abuse, Bethesda, Maryland 20892, USA.
Pharmacoeconomics. 2000 Oct;18(4):405-13. doi: 10.2165/00019053-200018040-00008.
To estimate the benefits of reduced cocaine consumption in terms of reduced societal costs resulting from the introduction of a medication for cocaine dependence with a small incremental treatment effect.
Cost-benefit analysis is applied to study the implications of reduced cocaine consumption. A modelling approach extrapolates the magnitude of treatment effects.
Epidemiological data on cocaine use and consumption as well as economic methods of cost-benefit analysis are utilised. Estimates of societal costs associated with heavy users of cocaine, who are most likely addicted and in need of immediate treatment, are developed using 1995 data.
In the first analysis, a postulated 1% reduction in consumption of cocaine among heavy users is examined to approximate a small treatment effect, resulting in a minimal consumption benefit. It is estimated that such a reduction would be valued at $US259 million. The cost-benefit analysis indicated that a cocaine medication with a small treatment effect (10 percentage point increase in abstinence rates) would result in a benefit to cost ratio in the range of 1.58 to 5.79, depending on prescribing behaviour and type of patient.
Such estimates of the benefits of these small treatment effects are conservative, and they may be biased downwards since the willingness to pay for such a cocaine medication could far exceed the benefit to cost estimation used in this paper. Nevertheless, the substantial benefits found in this paper indicate how important investment in cocaine medication is for public health policy; costs may be reduced with efficient prescribing behaviour. Market and governmental barriers to the utilisation of a cocaine medication could reduce the benefits and increase costs. Clinical trials, cost-effectiveness studies, and cost-benefit studies must be conducted to establish the actual pattern of benefits and costs that could be obtained for an efficacious and effective cocaine medication.
通过引入一种对可卡因依赖有较小增量治疗效果的药物,来估计减少可卡因消费在降低社会成本方面的益处。
应用成本效益分析来研究减少可卡因消费的影响。采用建模方法推断治疗效果的大小。
利用可卡因使用和消费的流行病学数据以及成本效益分析的经济方法。使用1995年的数据,对与最有可能成瘾且需要立即治疗的可卡因重度使用者相关的社会成本进行估计。
在首次分析中,考察了假定的可卡因重度使用者消费减少1%的情况,以近似一种较小的治疗效果,从而得出最小的消费效益。据估计,这种减少的价值为2.59亿美元。成本效益分析表明,一种治疗效果较小(戒断率提高10个百分点)的可卡因药物,其效益成本比在1.58至5.79之间,具体取决于处方行为和患者类型。
对这些小治疗效果益处的此类估计是保守的,而且可能向下偏差,因为为这种可卡因药物支付的意愿可能远远超过本文所采用的效益成本估计。然而,本文发现的巨大益处表明了对可卡因药物的投资对公共卫生政策有多重要;通过有效的处方行为可以降低成本。可卡因药物使用的市场和政府障碍可能会减少益处并增加成本。必须进行临床试验、成本效果研究和成本效益研究,以确定一种有效且高效的可卡因药物所能获得的实际效益和成本模式。